Interestingly, the previously mentioned study by Garcia-Aguilar et al. revealed that mutant TP53 alone is not associated with tumor response to CRT, but a TP53 mutation together with a KRAS gene mutation was identified as a possible predictor of a non-pCR to CRT [67]. This evidence concerns the gene KRAS and neoplasm.